entete

Les publications du Dr Steeve Provencher

 

Hypertension artérielle pulmonaire

  1. Nickel NP, Yuan K, Dorfmuller P, Provencher S, Lai YC, Bonnet S, Austin ED, Koch CD, Morris A, Perros F, Montani D, Zamanian RT, de Jesus Perez VA. Beyond the lungs: systemic manifestations of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2019 Sep 12. 
  2. Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay É, Omura J, Coté N, Abu-Alhayja'a R, Dumais V, Nachbar RT, Tastet L, Dahou A, Breuils-Bonnet S, Marette A, Pibarot P, Dupuis J, Paulin R, Boucherat O, Archer SL, Bonnet S, Potus F. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ Res. 2019 Aug 2;125(4):449-466.
  3. Bourgeois A, Bonnet S, Breuils-Bonnet S, Habbout K, Paradis R, Tremblay E, Lampron MC, Orcholski ME, Potus F, Bertero T, Peterlini T, Chan SY, Norris KA, Paulin R, Provencher S, Boucherat O. Inhibition of CHK1 (Checkpoint kinase 1) elicits therapeutic effects in pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1667-1681.
  4.  Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GP, Szulcek R, Bourgeois A, Lampron MC, Habbout K, Martineau S, Paulin R, Kulikowski E, Jahagirdar R, Schalij I, Bogaard HJ, Bartelds B, Provencher S, Berger RMF, Bonnet S, Goumans MJ. Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2019 May 1
  5. Sofianopoulou E, Kaptoge S, Gräf S, Hadinnapola C, Treacy CM, Church C, Coghlan G, Gibbs JSR, Haimel M, Howard LS, Johnson M, Kiely DG, Lawrie A, Lordan J, MacKenzie Ross RV, Martin JM, Moledina S, Newnham M, Peacock AJ, Price LC, Rhodes CJ, Suntharalingam J, Swietlik EM, Toshner MR, Wharton J, Wilkins MR, Wort SJ, Pepke-Zaba J, Condliffe R, Corris PA, Di Angelantonio E, Provencher S, Morrell NW. Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. Eur Respir J. 2019 May 30;53(5).
  6. F Tanguay V, Babin C, Giardetti G, Sohier-Poirier C, Ménard-Cholette V, Ranchoux B, Ruffenach G, Montani D, Bonnet S, Provencher S. Enhanced pulmonary artery radiodensity in Pulmonary Arterial Hypertension: A sign of early calcification? Am J Respir Crit Care Med. 2019 March 15;199(6):799-802
  7. Lai YC, Provencher S, Goncharova EA. TAKling GDF-15 and skeletal muscle atrophy in pulmonary hypertension: are we there yet? Thorax. 2019 Feb; 74(2): 103-105 
  8. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019 Jan 24; 53(1) 
  9. Guay CA, Morin-Thibault LV, Bonnet S, Lacasse Y, Lambert C, Lega JC, Provencher S. Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. Plos One. 2018 Oct 11;13(10):e0204610
  10. Couture EJ, Provencher S, Denault AY. Management of severe Pulmonary Hypertensive Disease for surgical and nonsurgical procedures. Int Anesthesiol Clin.Fall;56(4):e28-e55
  11. Lajoie AC, Bonnet S, Lacasse Y, Lega JC, Provencher SInterpreting risk reduction in clinical trials for pulmonary arterial hypertension. Eur Respir Rev. 2018 May 15;27(148).
  12. Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet S. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational researchCirculation Research. 2018 Mar 30;122(7):1021-1032
  13. Adao R, Mendes-Ferreira P, Santos-Ribeiro D, Maia-Rocha C, Pimentel L, Pinto C, Mulvaney EP, Reid HM, Kinsella BT, Potus F, Breuils-Bonnet S, Rademaker MT, Provencher S, Bonnet S, Leite-Moreira A, Bras-Silva C. Urocortin-2 improves right ventricular function in pulmonary arterial hypertension. Cardiovascular Research 2018 Jul 1;114(8):1165-1177.
  14. Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S, Potus F, Meloche J, Chabot S, Lambert C, Tremblay E, Chae YC, Altieri DC, Sutendra G, Michelakis ED, Provencher S, Bonnet S. Mitochondrial HSP90 accumulation promotes vascular remodeling in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2018 Jul 1;198(1):90-103.
  15. Bourgeois A, Lambert C, Habbout K, Paquet-Marceau S, Trinh I, Breuils-Bonnet S, Paradis R, Nadeau V, Paulin R, Provencher S, Bonnet S, Boucherat O. FOXM1 promotes pulmonary smooth muscle cell expansion in pulmonary arterial hypertension. J Mol Med (Berl) 2018 Feb;96(2):223-235. 
  16. Lajoie AC, Guay CA, Lega JC, Lauzière G, Simard S, Lambert C, Lacasse Y, Bonnet S, Provencher STrial duration and risk reduction in combination therapy trials for pulmonary arterial hypertension: A systematic review. Chest. 2018 May;153(5):1142-1152.
  17. Zabini D, Granton E, Hu Y, Miranda MZ, Weichelt U, Breuils-Bonnet S, Bonnet S, Morrell NW, Connelly KA, Provencher S, Ghanim B, Klepetko W, Olschewski A, Kapus A, Kuebler WM. Loss of SMAD3 promotes vascular remodeling in pulmonary arterial hypertension via MRTF disinhibition. Am J Respir Crit Care Med. 2018 Jan 15;197(2):244-260.
  18. Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, Paulin R, Bonnet S, Provencher SDual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulmonary Circulation. 2018 Jan-Mar;8(1)
  19. Malenfant S, Brassard P, Paquette M, Le Blanc O, Chouinard A, Nadeau V, Allan PD, Tzeng YC, Simard S, Bonnet S, Provencher SCompromised cerebrovascular regulation and cerebral oxygenation in pulmonary arterial hypertension. J Am Heart Assoc. 2017 Oct 12;6(10)
  20. Boucherat O, Provencher S, Bonnet S.Therapeutic Value of ASK1 in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2018 Feb 1;197(3):284-286
  21. Boucherat O, Chabot s, Paulin R, Trinh I, Bourgeois A, Potus F, Lampron MC, Lambert C, Breuils-Bonnet S, Nadeau V, Paradis R, Goncharova EA, Provencher S, Bonnet S. HDAC6: A novel histone deacetylase implicated in pulmonary arterial hypertension. Sci. Rep. 2017 Jul 3;7(1):4546
  22. Lajoie AC, Bonnet S, Provencher SClinical trial research in focus: improving drug development ad trial design in pulmonary arterial hypertensionLancet Respir Med. 2017 Jul;5(7):544-546
  23. Lajoie AC, Bonnet S, Provencher SCombination therapy in pulmonary arterial hypertension: recent accomplishments and future challengesPulm Circ. 2017 Apr-Jun;7(2):312-325
  24. Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulm. Circ. 2017 Apr-Jun;7(2):285-289
  25. Harel F, Langleben D, Provencher S, Fournier A, Finnerty V, Nguyen QT, Letourneau M, Levac X, Abikhzer G, Guimond J, Mansour A, Guertin MC, Dupuis J. Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principal trialEur J Nucl Med Mol Imaging. 2017 Jul;44(7):1136-1144.
  26. Meloche J, Lampron MC, Nadeau V, Maltais M, Potus F, Lambert C, Tremblay E, Vitry G, Breuils-Bonnet S, Boucherat O, Charbonneau E, Provencher S, Paulin R, Bonnet S. Implication of inflammation and epigenetics Readers in Coronary Artery Remodeling in patients with pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1513-1523. 
  27. Perros F, Humbert M, Nazzareno G, Simmoneau G, Bogaard HJ, de Man F, Antigny F, Provencher S, Bonnet S, Galiè N, Humbert M.. Use of beta-blockers in pulmonary hypertension. Circulation: Heart Failure. 2017 Apr;10(4) pii:e003703
  28. Hong Z, Chen K, Dasgupta A, Potus F, Dunham-Snary K, Bonnet S, Tian L, Fu J, Breuils-Bonnet S, Provencher S, Archer SL. miR-138 and miR-125 downregulate MCU, causing pulmonary arterial hypertension's cancer phenotype. Am J Resp Crit Care Med. 2017 Feb 15; 195(4):515-529 
  29. Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M. Translating research into improved patient care in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2017 Mar1;195(5):583-85 
  30. Ranchoux B*, Meloche J*, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA damage and pulmonary hypertension. International Journal of Molecular Sciences. 2016 Jun 22;17(6).
  31. Bonnet S and Provencher S. Shear stress maladaptation in pulmonary arterial hypertension: an ageless concept. Am J Resp Crit Care Med.2016 Jun 15;193(12):1331-2
  32. Ruffenach*, Chabot S*, Tanguay VF, Courboulin A, Boucherat O, Potus f, Meloche J, Pflieger A, Breuils-Bonnet S, Nadeau V, Paradis R, Girerd B, Hautefort A, Montani D, Fadel E, Dorfmuller P, Humbert M, Perros F, Paulin R, Provencher S, Bonnet S. RUNX2 in proliferative and calcified vascular lesions seen in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2016 Nov15;194(10):1273-1285 
  33. Antigny F, Hautefort A, Meloche J, Belacel-Ouari M, Manoury B, Rucker-Martin C, Péchoux C, Potus F, Nadeau V, Tremblay E, Ruffenach G, Bourgeois A, Dorfmuller P, Breuils-Bonnet S, Fadel E, Ranchou B, Jourdon P, Girerd B, Montani D, Provencher S, Bonnet S, Simmoneau G, Humbert M, Perros F. Potassium-channel subfamily K-member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation. 2016 April 5;133 (14):1371-85
  34. Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respi Med. 2016 Apr;4(4):291-305. 
  35. Antigny F, Hautefort A, Meloche J, Belacel-Ouari M, Manoury B, Rucker-Martin C, Péchoux C, Potus F, Nadeau V, Tremblay E, Ruffenach G, Bourgeois A, Dorfmuller P, Breuils-Bonnet S, Fadel E, Ranchou B, Jourdon P, Girerd B, Montani D, Provencher S, Bonnet S, Simmoneau G, Humbert M, Perros F. Potassium-channel subfamily K-member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation. 2016 April 5;133(14):1371-85  
  36. Potus F, Le guen M, Provencher S, Meloche J, Bonnet S. DNA damage at the dawn of micro-RNA pathway impairment in pulmonary arterial hypertension. RNA & DISEASE 2015 (2) :e810
  37. Boucherat O, Chabot S, Antigny F, Perros F, Provencher S, Bonnet S. Potassium channels in pulmonary arterial hypertension. Eur Respir J. 2015 Oct;46(4):1167-77. Review
  38. Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson IH, Deschamps L, Chabot S, Ruffenach GN, Henry S, Breuils-Bonnet S, Tremblay È, Nadeau V, Lambert CM, Paradis R, Provencher S, Bonnet S. Bromodomain Containing Protein-4: The epigenetic origin of pulmonary arterial hypertension. Circ Res. 2015 Aug 28;117(6):525-35.
  39. Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, Nadeau V, Paradis R, Graydon C, Wong R, Johnson I, Paulin R, Lajoie AC, Perron J, Charbonneau E, Joubert P, Pibarot P, Michelakis ED, Provencher S, Bonnet S. Downregulation of miR-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation. 2015 Sep 8;132(10):932-43.
  40. Meloche J, Le Guen M, Potus F, Vinck J, Ranchoux B, Johnson I, Antigny F, Tremblay E, Breuils-Bonnet S, Perros F, Provencher S, Bonnet S. MiR-223 reverses experimental pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2015 Sep 15;309(6):C363-72.
  41. Malenfant S, Potus F, Mainguy V, Leblanc È, Malenfant M, Ribeiro F, Saey D, Maltais F, Bonnet S, Provencher S. Impaired skeletal muscle oxygenation and exercise tolerance in pulmonary hypertension. Med Sci Sports Exerc. 2015 Nov;47(11):2273-82.
  42. Provencher S, Granton JT. Current treatment approaches to pulmonary arterial hypertension. Can J Cardiol. 2015 Apr;31(4):460-77.
  43. Provencher S, Paruchuru P, Spezzi A, Waterhouse B, Gomberg-Maitland M, on behalf of the pH12 Flolan reformulation study group. Quality of Life, Safety and Efficacy profile of thermostable Flolan in pulmonary arterial hypertension. PLOS ONE. 2015 Mar 20;10(3).
  44. Malenfant S, Potus F, Fournier F, Breuils-Bonnet S, Pflieger A, Bourassa S, Tremblay È, Nehmé B, Droit A, Bonnet S, Provencher S. Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension. J Mol Med (Berl). 2015 May;93(5):573-84.
  45. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy AS, Provencher S, Bonnet S, Michelakis E. A miR-208-Mef2 axis drives the de-compensation of right ventricular function in Pulmonary Hypertension. Circ Res. 2015;116(1):56-69.
  46. Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol. 2015;13(3):331-40
  47. Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, Haromy A, Webster L, Provencher S, Bonnet S, Michelakis ED. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab. 2014 Nov 4;20(5):827-39.
  48. Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, Breuils-Bonnet S, Mai D, Navab K, Ross D, Navab M, Provencher S, Fogelman AM, Bonnet S, Reddy ST, Eghbali M. Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3p. Circulation 2014; 130(9): 776-85.
  49. Potus F, Malenfant S, Graydon C, Mainguy V, Tremblay E, Breuils-Bonnet S, Ribeiro F, Porlier A, Maltais F, Bonnet S, Provencher S. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 190(3): 318-28.
  50. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulous S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014: 129(7): 786-97.
    Titulaire du "Sir John Vane Award" pour la meilleure publication récente en lien avec les maladies vasculaires pulmonaires.
  51. Paulin R, Meloche J, Courboulin A, Lambert C, Haromy A, Courchesne A, Bonnet P, Provencher S, Michelakis ED, Bonnet S. Targeting cell motility in pulmonary arterial hypertension. Eur Respir J. 2014; 43(2): 531-44.
  52. Chaouat A, Sitbon O, Mercy M, Ponçot-Mongars R, Provencher S, Guillaumot A, Gomez E, Selton-Suty C, Malvestio P, Regent D, Paris C, Hervé P, Chabot F. Pronostic value of exercise cardiac index in idiopathic, familial and anorexigen-associated pulmonary arterial hypertension. Eur Respir J 2014; 44(3): 704-13.
  53. Meloche J, Pflieger A, Vaillancourt M, Graydon C, Provencher S, Bonnet S. miRNAs in PAH: biomarker, therapeutic target or both? Drug Discovery Today 2014; 19(8): 1264-9.
  54. Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension with focus on miR-204 and miR126. Pulm Circ 2014; 4(2): 175-84.
  55. Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of pulmonary arterial hypertension specific therapies on health-related quality of life: a systematic review. Chest 2014; 146(3):1-23.
  56. Mainguy V, Malenfant S, Neyron AS, Saey D, Maltais F, Bonnet S, Provencher S. Alternatives to the six-minute walk test in pulmonary arterial hypertension. PlosOne 2014; 9(8): e103626.
  57. Vonk Noordegraaf A, Haddad F, Chin KM, Forfia Pr, Dawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel N, Hassoun PM. Right Heart Adaptation to Pulmonary Arterial Hypertension: Physiology and Pathobiology. J Am Coll Cardiol 2013; 62(25 suppl): D22-33.
  58. Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pivarot P, Bonnet S, Provencher S.   Pim-1: a new biomarker in pulmonary arterial hypertension. Pulmonary Circulation 2013; 3(1): 74-81.
  59. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay E, Biardel S, Racine C, Couture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S. Critical Role of the Advanced Glycation Endproducts Receptor in Pulmonary Arterial Hypertension Ethiology. J Am Heart Assoc 2013; 2:e005157 doi: 10.1161/JAHA.112.00515
  60. Provencher S, Renard S, Rival G. Exploration pulmonaire par cathétérisme droit. EMC-Pneumologie 2013; 10(1): 1-10. [Article 6-000-F-20].
  61. Malenfant S, Margaillan G, Loehr J, Bonnet S, Provencher S. The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to near future. Expert Review of Respiratory Medicine 2013; &(1): 1-13.
  62. Mainguy V, Malenfant S, Neyron AS, Bonnet S, Maltais F, Saey D, Provencher S. Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension. Eur Respir J 2013 Aug;42(2):425-34 
  63. Barrier M, Meloche J, Jacob MH, Courboulin A, Provencher S, Bonnet S. Today’s and tomorrow’s imaging and circulating biomarkers for pulmonary arterial hypertension. Cell Mol Life Sci; 2012;69:2805-31.
  64. Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, Lambert C, Jacob MH, Bonnet SN, Provencher S, Bonnet S. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J. 2012; 40(3): 618-629.
  65. Provencher S, Mainguy V. Exercise testing in Pulmonary Arterial Hypertension. Progress in Respiratory Research : Pulmonary Vascular disorders. Krager 2012, Vol. 41, pp 37-47. Editor CT Bolliger. ISBN 978-3-8055-9914-4.
  66. Mainguy V, Provencher S. Le test de marche: un outil essentiel en pneumologie. La Lettre du Pneumologue 2012; 6: 162-6.
  67. Provencher S, Bonnet S. Pulmonary arterial hypertension research: Why does it take so long? How can I contribute? Connections 2012; 3(2): 26-7.
  68. Provencher S, Chemla D, Hervé P. Hémodynamique de repos et d’effort dans l’hypertension artérielle pulmonaire / Resting and exercise hemodynamics in pulmonary arterial hypertension. La Presse Médicale 2011;40 :1528-1538.
  69. Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, Bisserier M, Paulin R, Lambert C, Provencher S, Bonnet S. Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011; 12(1):128.
  70. Mainguy V, Provencher S, Maltais F, Malenfant S, Saey D. Assessment of Daily Life Physical activities in Pulmonary Arterial Hypertension. Plos One 2011; 6(11): e27993
  71. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Sassouk N, Coté J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/Pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011; 123(11): 1205-1215.
  72. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perrault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S. A critical role of microRNAs in human pulmonary arterial hypertension. miR-204: a novel therapeutic target. J Exp Med 2011;208(3):535-48.
  73. Provencher S, Chemla D, Hervé P. Hémodynamique de repos et d’effort dans l’hypertension artérielle pulmonaire / Resting and exercise hemodynamics in pulmonary arterial hypertension. La Presse Médicale 2011;40 (suppl 1) :1S28-38. (corresponding author)
  74. Mehta S, Helmersen D, Provencher S, Hirani N, Rubens FD, De Perrot M, Blostein M, Boutet K, Chandy G, Dennie C, Granton J, Hernandez P, Hirsch AM, Laframboise K, Levy RD, Lien D, Martel S, Shoemaker G, Swiston J, Weinkauf J; for the Canadian Thoracic Society Pulmonary Vascular Disease - CTEPH CPG Development Committee; and the Canadian Thoracic Society Canadian Respiratory Guidelines Committee. Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: A clinical practice guideline. Can Respir J. 2010;17(6):301-334.
  75. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Effects of a rehabilitation program on skeletal muscle function in idiopathic pulmonary arterial hypertension. J Cardiopulm Rehabil Prev 2010;30(5): 319-23.
  76. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Peripheral Muscle Dysfunction in Idiopathic Pulmonary Arterial Hypertension. Thorax 2010; 65(2) : 113-117.
  77. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galié N, Gibbs JSR, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End Points and Clinical Trial Design in PAH. J Am Coll Cardiol 2009; 54(1): S97-107.
  78. Grünig E, Weissmann S, Ehlken N,Fijalkowska A, Fischer C, Fourme T, Galié N, Ghofrani A, Harrison RE, Huez S, Humbert M, Janssen B, Kober J, Koehler R, Machado RD, Mereles D, Naeije R, Olschewski H, Provencher S, Reichenberger F, Retailleau K, Rocchi G, Simonneau G, Torbicki A, Trembath R, Seeger W. Stress-Doppler-echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009;119:1747-1757.
  79. Chemla D, Castelain V, Provencher S, Humbert M, Simonneau G, Hervé P. Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest 2009;135(3):760-8.
  80. Provencher S, Hervé P., Sitbon O, Humbert M, Simonneau G, Chemla D. Changes in Exercise hemodynamics during treatment in Pulmonary Arterial Hypertension. Eur Respir J 2008; 32: 393-398
  81. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27(5):589-95.
  82. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006;130(1):120-6.
  83. Provencher S, Chemla D, Hervé P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J 2006; 27(1):114-20.
  84. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111(23):3105-11.

 

Embolie pulmonaire

  1. Belzile D, Jacquet S, Bertoletti L, Lacasse Y, Lambert C, Lega J.C, Provencher S. Outcomes following a negative computed tomography pulmonary angiography according to pulmonary embolism prevalence: a meta-analysis of the management outcome studies. Journal of Thrombosis and Haemostasis 2018 16:6 (1107-1120) 
  2. Lega JC, Lacasse Y, Lakhal L, Provencher S.   Natriuetic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 2009; 64 : 869-875

 

État post-pneumonectomie

  1. Deslauriers J, Ugalde P, Miro S, Ferland S, Bergeron S, Lacasse Y, Provencher S. Adjustments in cardiorespiratory function after pneumonectomy: results of the pneumonectomy project. J Thorac Cardiovasc Surg. 2011 Jan;141(1):7-15
  2. Deslauriers, J, Ugalde P, Miro S, Deslauriers D, Ferland S, Bergeron S, Lacasse Y, Provencher S. Long-term physiologic consequences of pneumonectomy. Semin in Thorac and Cardiovasc Surg 2011;23(3) :196-202.
  3. Ugalde P, Miro S, Provencher S, Quevillon M, Chau L, Deslauriers DR, Lacasse Y, Ferland S, Simard S, Ferland S, Deslauriers J. Ispsilateral diaphragmatic motion and lung function in long-term pneumonectomy patients. Ann Thorac Surg 2008; 86(6):1745-51.

 

Maladie pulmonaire obstructive chronique

  1. Boucherat O, Morissette MC, Provencher S, Bonnet S, Maltais F. Bridging lung development with COPD: Relevance of developmental pathways in COPD pathogenesis. Am J Respir Crit Care Med. 2016 Feb 15;193(4):362-75
  2. Gagnon P, Casaburi R, Saey D, Porszasz J, Provencher S, Milot J, Bourbeau J, O'Donnell DE, Maltais F. Cluster analysis in patients with GOLD 1 Chronic Obstructive Pulmonary Disease. PLOS ONE. 2015 Apr 23;10(4).
  3. Gagnon P, Lemire BB, Dubé A, Saey D, Porlier A, Croteau M, Provencher S, Debigaré R, Maltais F. Preserved function and reduced angiogenesis potential of the quadriceps in patients with mild COPD. Respir Res 2014; 15(1):4.
  4. Coates AL, Graham BL, McFadden RG, McParland C, Moosa D, Provencher S, Road J. Spirometry in Primary Care: a Canadian Thoracic Society Position Paper. Can Respir J 2013; 20(1): 13-21.
  5. Borel B, Provencher S, Saey D, Maltais F. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulmonary medicine 2013; 2013, Article ID 410748, 11 pages. doi:10.1155/2013/410748.
  6. Gagnon P, Saey D, Provencher S, Milot J, Bourbeau J, Tan, WC, Martel S, Maltais F. Walking exercise response to bronchodilation in mild COPD: A randomized trial. Respiratory Medicine 2012; 106(12): 1695-705. 
  7. Gagnon P, Bussières J, Ribeiro F, Gagnon S, Saey D, Gagné N, Provencher S, Maltais F. Influences of spinal anesthesia on exercise tolerance in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186(7) :606-615.
  8. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Sénéchal M, Poirier P, Provencher S.   Effects of Bisoprolol on respiratory function and exercise capacity in COPD. Am J Cardiol. 2012;110(2):258-63
  9. Bédard ME, Brouillard C, Pepin V, Provencher S, Milot J, Lacasse Y, Leblanc P, Maltais, F. Tiotropium improves walking endurance in patients with chronic obstructive pulmonary disease. Eur Respir J 2012;39(2):265-71.
  10. Deschenes D, Provencher S, Cormier Y. Framer's Lung-Induced Hypersensitivity Pneumonitis Complicated By Shock. Respiratory Care 2012; 57(3):464-6.
  11. Bédard ME, Marquis K, Poirier P, Provencher S. Reduced Heart Rate Variability in Patients With Chronic Obstructive Pulmonary Disease independent of anticholinergic or ß-agonist medications. COPD 2010;7:391-397
  12. Laviolette L, Lands LC, Dauletbaev N, Saey D, Milot J, Provencher S, LeBlanc P, Maltais F. Combined effect of dietary supplementation with pressurized whey and exercise training in COPD: a randomized controlled double-blind pilot study. J Med Food 2010;13(3):589-98
  13. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Peripheral Muscle Dysfunction in Idiopathic Pulmonary Arterial Hypertension. Thorax 2010; 65(2) : 113-117.
  14. Gagnon P, Saey D, Vivodtzev I, Laviolette L, Mainguy V, Milot J, Provencher S, Maltais F. Impact of pre-induced quadriceps fatigue on exercise response in chronic obstructive pulmonary disease and healthy subjects. J Appl Physiol. 2009;107(3):832-40

 

Autres

  1. Bonnet S, Boucherat O, Paulin R, Wu D, Hindmarch CCT, Archer SL, Song R, Moore JB 4th, Provencher S, Zhang L, Uchida S. Clinical values of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. Am J Physiol Cell Physiol. 2019 Sep 4.
  2. Mai V, Guay CA, Perreault L, Bonnet S, Bertoletti L, Lacasse Y, Jardel S, Lega JC, Provencher SExtended anticoagulation for VTE: a systematic review and meta-analysis. Chest. 2019 Jun;155(6):1199-1216. 
  3. Mai V, Bertoletti L, Cucherat M, Jardel S, Grange C, Provencher S, Lega JC. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PLoS One. 2019 Apr 1;14(4):e0214134.
  4. Guimaraes L, Lindenfeld J,  Sandoval J, Bayés-Genis A,  Bernier M,  Provencher S, Rodés-Cabau J. Interatrial shunting for heart failure current evidence and future perspectives.  EuroIntervention. 2019 Jun 20;15(2):164-171 
  5. Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, Hot A, Reynaud Q, Lega JC. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systemaic review and meta-analysis. Autoimmun Rev. 2019 Feb;18(2):113-122.
  6. Bussières JS, Moreault O, Couture EJ, Provencher S. Optimizing lung collapse with a bronchial blocker: it's not what you use, but how you use it, part II. J Cardiothorac Vasc Anesth. 2019 Jan; 33(1):255
  7. Couture EJ, Provencher S, Somma J, Lellouche F, Marceau S, Bussières JS. Effect of position and positive pressure ventilation on functional residual capacity in morbidly obese patients: a randomized trial. Can J Anaesth. 2018 May;65(5):522-528.
  8. Morin-Thibault LV, Wiseman D, Fortin M, Couture C, Provencher S. Pulmonary micro-tumor emboli resulting in paradoxical emboli: a case report. Pulm Circ. 2018 Apr-Jun;8(2):2045893218754853.
  9. Ryerson C, Camp PG, Eves ND, Schaeffer M, Syed N, Dhillon S, Jensen D, Maltais F, O'Donnell DE, Raghavan N, Roman M, Stickland MK, Assayag D, Bourbeau J, Dion G, Fell CD, Hambly N, Johannson KA, Kalluri M, Khalil N, Kolb M, Manganas H, Moran-Mendoza O, Provencher S, Ramesh W, Douglass Rolf J, Wilcox PG, Guenette JA. High oxygen delivery to preserve exercise capacity in Idiopathic Pulmonary Fibrosis treated with Nintedanib, Methodology of the HOPE-IPF Study. Ann Am Thorac Soc. 2016 Sep;13(9):1640-7
  10. Labbé C, Beaudoin S, Martel S, Delage A, Drapeau C, Provencher S. Diagnostic yield of non-guided flexible bronchoscopy for peripheral pulmonary neoplasia. Thoracic Cancer 2015 Jul;6(4):517-23
  11. Fortin M, Turgeon PY, Nadreau É, Grégoire P, Maltais LG, Sénéchal M, Provencher S, Maltais F. Prognostic value of oxygen kinetics during recovery from cardiopulmonary exercise testing in patients with chronic heart failure. Can J Cardiol. 2015 Oct;31(10):1259-65 
  12. Ferland N, Couture C, Provencher S. Near-fatal haemoptysis as presentation of a giant intralobar pulmonary sequestration. Eur Respir Rev. 2015 Mar;24(135):155-6.
© 2012 Université Laval. Tous droits réservés